{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:27:22Z","timestamp":1751398042613,"version":"3.37.3"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s11060-019-03289-7","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T20:03:40Z","timestamp":1568145820000},"page":"399-402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fatal encephalopathy after pembrolizumab treatment for advanced non-small cell lung carcinoma"],"prefix":"10.1007","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7162-414X","authenticated-orcid":false,"given":"Cl\u00e1udia","family":"Freitas","sequence":"first","affiliation":[]},{"given":"Lu\u00edsa","family":"Sampaio","sequence":"additional","affiliation":[]},{"given":"Gabriela","family":"Fernandes","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"key":"3289_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"key":"3289_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.1912","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN et al (2017) Neurological complications associated with anti\u2013programmed death 1 (PD-1) antibodies. JAMA Neurol. \nhttps:\/\/doi.org\/10.1001\/jamaneurol.2017.1912","journal-title":"JAMA Neurol"},{"key":"3289_CR3","volume-title":"Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors","author":"S Feng","year":"2017","unstructured":"Feng S, Coward J, McCaffrey E et al (2017) Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors. J. Thorac, Oncol"},{"key":"3289_CR4","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-15-0141","author":"C Maurice","year":"2015","unstructured":"Maurice C, Schneider R, Kiehl T-R et al (2015) Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol Res. \nhttps:\/\/doi.org\/10.1158\/2326-6066.cir-15-0141","journal-title":"Cancer Immunol Res"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-019-03289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-019-03289-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-019-03289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T10:28:58Z","timestamp":1599733738000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-019-03289-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,10]]},"references-count":4,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["3289"],"URL":"https:\/\/doi.org\/10.1007\/s11060-019-03289-7","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"type":"print","value":"0167-594X"},{"type":"electronic","value":"1573-7373"}],"subject":[],"published":{"date-parts":[[2019,9,10]]},"assertion":[{"value":"30 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The report of this case was approved by Ethics Committee of Centro Hospitalar e Universit\u00e1rio de S\u00e3o Jo\u00e3o.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}